# Compare Efficacy/Safety of Repeat Doses of Ferumoxytol With Iron Sucrose in CKD Subjects With IDA and on Hemodialysis

Study · id `cardio:ct-nct01227616` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01227616](<https://clinicaltrials.gov/study/NCT01227616>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01227616

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 296 participants.

## Technical summary

Registry record NCT01227616. Randomized; no masking; primary purpose treatment. Start 2013-08 (actual); primary completion 2016-02 (actual). Results posted on 2019-07-19.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 296 participants (enrolled count; ClinicalTrials.gov record NCT01227616, source copy `cardio:ctgov-nct01227616-2022-04-21`, retrieved 2026-10-26)
- Started: 2013-08 (actual) (ClinicalTrials.gov record NCT01227616, source copy `cardio:ctgov-nct01227616-2022-04-21`, retrieved 2026-10-26)
- Primary completion: 2016-02 (actual) (ClinicalTrials.gov record NCT01227616, source copy `cardio:ctgov-nct01227616-2022-04-21`, retrieved 2026-10-26)
- Completion: 2017-02 (actual) (ClinicalTrials.gov record NCT01227616, source copy `cardio:ctgov-nct01227616-2022-04-21`, retrieved 2026-10-26)
- Results first posted: 2019-07-19 (ClinicalTrials.gov record NCT01227616, source copy `cardio:ctgov-nct01227616-2022-04-21`, retrieved 2026-10-26)
- Countries: United States; Canada; United Kingdom (ClinicalTrials.gov record NCT01227616, source copy `cardio:ctgov-nct01227616-2022-04-21`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01227616-2022-04-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: Compare Efficacy/Safety of Repeat Doses of Ferumoxytol With Iron Sucrose in CKD Subjects With IDA and on Hemodialysis
- Condition: Iron Deficiency Anemia Treatment
- Condition: Chronic Kidney Disease(CKD)
- Intervention (Drug): Ferumoxytol
- Intervention (Drug): Iron Sucrose
- Lead sponsor: AMAG Pharmaceuticals, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: AMAG Pharmaceuticals, Inc. (`cardio:org-amag-pharmaceuticals-inc`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Ferumoxytol for iron deficiency anemia in patients undergoing hemodialysis. The FACT randomized controlled trial (`cardio:pubmed-30802204`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: The Ferumoxytol for Anemia of CKD Trial (FACT)-a randomized controlled trial of repeated doses of ferumoxytol or iron sucrose in patients on hemodialysis: background and rationale (`cardio:pubmed-28372549`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 0afaf356599c7e9c1514170a0e9577c3ad61d68a1db6b573fbabf1ea9bde6296
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
